Cingulate up on completing trial of lead drug candidate

Cingulate

08/06/2023 15:36

** Shares of biopharma co Cingulate Inc  CING.O  up 4.3% at
98 cents
    ** Co completes late-stage study for dose-optimization of
its experimental drug, CTx-1301, for attention
deficit-hyperactivity disorder (ADHD) in adults
    ** Expects to report results in Q3
    ** Says it is on track to initiate trials in pediatric and
adolescent patients in Q3
    ** Co plans to apply for marketing approval in mid-2024
    ** Stock down 2% YTD

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))